WELCOME TO WINDTREE THERAPEUTICS
Windtree Therapeutics Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. Windtree’s proprietary technology platform includes a synthetic, treatment peptide-containing surfactant KL4 surfactant that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant. Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival. Premature infants born prior to 37 weeks gestational age may not have fully developed natural pulmonary surfactant and therefore may need surfactant therapy to sustain life. Respiratory distress syndrome (RDS) in premature infants is a serious respiratory condition resulting from surfactant insufficiency that can lead to long-term respiratory problems, developmental delay and death. Windtree is focused initially on improving the management of RDS in premature infants and has received orphan drug designation in both the U.S. and E.U. for this indication. Windtree believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases characterized by surfactant deficiency or dysfunction, for which there are few or no approved therapies.